MITT population (N = 42)
Parametera	Clinical response n/N (%), (95% CI)	Microbiologic response n/N (%), (95% CI)	Global response n/N (%), (95% CI)
End of all therapy (EOT)	32/34 (94.1%), (80.3, 99.3)	34/35 (97.1%), (85.1, 99.9)	31/36 (86.1%), (70.5, 95.3)b
End of IV therapy	34/35 (97.1%), (85.1, 99.9)	36/37 (97.3%), (85.8, 99.9)	33/37 (89.2%), (74.6, 97.0)
2 weeks after EOT	26/28 (92.9%), (76.5, 99.1)	25/29 (86.2%), (68.3, 96.1)	24/29 (82.8%), (64.2, 94.2)
6 weeks after EOT	17/18 (94.4%), (72.7, 99.9)	17/18 (94.4%), (72.7, 99.9)	17/19 (89.5%), (66.9, 98.7)
12 weeks after baseline	17/20 (85.0%), (62.1, 96.8)	16/19 (84.2%), (60.4, 96.6)	16/22 (72.7%), (49.8, 89.3)

^aMissing/indeterminate responses excluded.

^bPrimary endpoint.